An analysis of linear antibody-binding sites of the glycoprotein B (gB) molecule ofmurine cytomegalovirus (MCMV) and of genetic variation within these regions was performed. To achieve this, a series of overlapping fragments spanning the entire coding sequence of the gB gene of the K181 strain of MCMV was expressed in E. coli as fusion proteins with glutathione S-transferase (GST) using the pGEX expression system. Four antibody-binding regions were mapped to locations spanning amino acid residues 17-79 (BS), 155-278 (BE2), 809-926 (SS) and 347-508 (BB and EE), based on reactivity in Western blot analysis of GST-gB fusion proteins with murine polyclonal antiserum raised against MCMV. Only the antibody-binding region BE2 (155-278) elicited an antiserum that exhibited complementdependent neutralizing activity, and immunization of mice with the fusion protein BE2 led to moderate but significant reductions in the level of MCMV replication in the spleen. Polyclonal antisera raised against the GST-gB fusion proteins detected purified virion proteins of 105 kDa (anti-BS and anti-BE2) and 52 kDa (anti-SS), and are therefore likely to recognize the N-terminal and C-terminal portions of the gB molecule, respectively. The antibody-binding region within amino acid residues 17-79 was found to be MCMV strain-specific, whereas antibody-binding regions within residues 155-278 and 809-926 were found to be conserved among MCMV field isolates. Comparative sequence analysis of the corresponding regions of MCMV gB revealed a level and extent of sequence heterogeneity consistent with these findings.
Introduction
The nucleotide and deduced amino acid sequences reported in this paper have been submitted to the Genome Sequence Data Base and assigned the accession numbers L39243-L39251, L39215 L39228, L39252-L39260 and L39229-L39242. potential candidates for inclusion as components of a subunit vaccine (Blacklaws et al., 1990; Spear, 1985; Ghiasi et al., 1994) . It has been estimated that a significant proportion of the neutralizing antibodies in sera from individuals infected with human cytomegalovirus (HCMV) is directed against glycoprotein B (gB), suggesting that HCMV gB represents a predominant antigen for the induction of neutralizing antibodies G6ncz61 et al., 1991; Rasmussen, 1990) . HCMV gB constitutes the glycoprotein complex gcI which contains disulphide-linked molecules of 55 and 116 kDa Cranage et al., 1986; Gretch et al., 1988) . The HCMV gB gene has been expressed in both prokaryotic and eukaryotic systems and a number of conformation-dependent, as well as conformationindependent antigenic epitopes have been identified (reviewed by Rasmussen, 1990 Rasmussen, , 1993 . In addition, there is also evidence that gB activates cytotoxic T lymphocytes in naturally infected, seropositive humans (Borysiewicz et al., 1988; Liu et al., 1991; Riddell et al., 1991) . These data imply that gB is likely to be a primary candidate for inclusion in a subunit HCMV vaccine. However, comparative sequence analysis of certain antigenic regions of the gB gene from different strains of HCMV has revealed that there is sequence variation among strains, although there are certain regions that are highly conserved (Lehner et Because of the strict species specificity of the cytomegaloviruses it has not been possible to establish a direct animal model for HCMV. However, murine cytomegalovirus (MCMV), which resembles its human counterpart in many of its properties, serves as a useful model system for studying HCMV infection (Hudson, 1979 (Xu et al., 1994b) . The MCMV gB gene has been shown to encode the major glycoprotein complex defined by the gp52, gpl05, gp128 and gpl50 molecules. Both neutralizing and non-neutralizing antibodies with specificity to MCMV gB have been produced (Rapp et al., 1992; Loh et al., 1988) . While the gp52 and gpl05 proteins have been shown to be cleaved from gpl50 (Loh et al., 1988; Loh, 1991) , to date, the relevant antigenic epitopes present on gB have not been characterized. In this study, we describe the expression of the MCMV gB gene in E. coli and the identification of a subset of antibody-binding regions present on gB as defined by the reactivity of anti-MCMV sera with the gB fusion proteins. We have also evaluated the neutralizing activity of anti-gB antisera to MCMV in vitro and the protective potential of the antibody response to the gB fusion proteins in vivo. Furthermore, we have tested the antigenic variation among different strains of MCMV using antisera to the identified antigenic regions. Finally, we have performed comparative sequence analysis of these regions and found that the pattern of sequence heterogeneity is consistent with antibody reactivity.
Methods
Virus and cell culture. The MCMV strains used in this study included the laboratory strain K181, and the MCMV field isolates G1A, G2, G3A, G3B, G3E, (34, G5, W2, W3, W4, W5, W7, W8, WE6, W8211,   W9077, K4, K6, K7, K10, K17A , K17B, K17E, K29 and N1 (Booth et al., 1993) . The MCMV strains were propagated in mouse embryo fibroblasts (MEF) by standard procedures (Farrell & Shellam, 1989) . The K181 strain was also maintained by serial passage in the salivary glands of mice as described previously (Allan & Shellam, 1984) . Purification of MCMV virions was carried out essentially according to the method described by Kim et al. (1976) , and viral DNA was prepared as previously described (Mocarski et al., 1980) , except that the lysis buffer used contained 0.5 % (v/v) sodium deoxycholate and 1% (v/v) NP40. To prepare infected MEF lysates, MEF monolayers were infected with 10 p.f.u, per cell using the technique of centrifugal enhancement at 800 g for 30 min. Infected cells were harvested at 28 h post-infection and lysed with lysis buffer (50 mM-Tris-HC1, pH 7.4, 150 mM-NaC1, 1% Triton X-100, 1% sodium deoxycholate, 2 mM-PMSF (Sigma), 1 ~g/ml aprotinin and 100 units/ml DNase).
Protein sequence analysis. Sequence analysis, including estimations of the antigenic index, hydrophilicity, flexibility and surface probability throughout the MCMV gB molecule was done using the MacVector sequence analysis program, version 3.5 (IBI).
PCR and construction of gB plasmids containing Jull-length gB or subfragments ofgB. The gB coding sequence was amplified by PCR from K181 MCMV genomic DNA using primers which introduced BamHI sites flanking the coding sequence. Primer 1 (5' ACACTGGATCcCTGAACAACGCTCG 3') corresponds to uucleotides 258-276 (underlined), and primer 2 (5' CTGTCAGGaTCCATGCCGGACTGTA 3') corresponds to nucleotides 3230-3247 (underlined) of the published sequence of the gB gene of MCMV Smith strain (Rapp et al., 1992) . Single nucleotide mismatches to introduce BamHI sites in both primers were achieved by replacing a G with a C in primer 1, and a T with an A in primer 2 (both shown in lower case). PCR amplifications were performed under the following optimal conditions using 100 ng of K181 DNA as template, 2 mM-MgC12, 0.2 mM-dNTPs, 10 pmol of each of the primers, 1 unit of Taq DNA polymerase and 1 × Taq buffer (Promega) in a final volume of 50 ~tl. The PCR amplification of the gB fragment was confirmed by restriction enzyme analysis, which showed that the gB sequence of the K181 strain and the Smith strain have identical restriction enzyme patterns for the restriction enzymes AvaI, BglI, AecI, SaII, StuI, BclI, EcoRI, EcoRV, BglII, Bali, NheI, HincII, XhoII, PvuII and ScaI. The gB coding sequence of K 181 strain has been determined in part (shown in Fig. 5 ). All this suggests that the gB coding sequence of K181 has an identical reading frame to that of the Smith strain, and also provides a basis for the construction of K181 gB subfragments to give in-frame insertions in the pGEX expression vectors (Smith & Johnson, 1988) .
The amplified K181 gB DNA fragment was digested with BamHI and subcloned into the BamHI site ofpBR322. This plasmid was designated pBR322-gB. Subfragments ofgB were generated by digesting pBR322-gB or the gB PCR product with appropriate restriction enzymes (Promega). Restriction fragments were blunt-ended with Klenow or T4 DNA polymerase and cloned into the appropriate pGEX expression vector to give the correct reading frame (Smith & Johnson, 1988) . The correct insertion of DNA fragments was verified by restriction enzyme and Southern blot analysis, and by selecting clones which gave rise to fusion proteins with the correct predicted molecular mass.
Induction and purification of fusion proteins. Recombinant GST-gB fusion proteins were produced in E. eoli XL-1 blue cells by a modified version of the original method described by Smith & Johnson (1988) . Briefly, overnight cultures were diluted 1 / 10 in 2YT medium containing 50 ~g/ml ampicillin and grown at 37 °C for 1 h. IPTG was added to a final concentration of 1 mM to induce expression of the fusion protein.
After a further 3-7 h of growth, cells were pelleted, lysed in SDS gel sample buffer, and proteins separated by SDS-PAGE on 10% gels (Laemmli, 1970) .
Insoluble fusion proteins were enriched by washing cell pellets three times in TBS containing 1% (v/v) Triton X-100, and then solubilized in 5 ml of TBS containing 0.1 mM-PMSF and 8 M-urea. Enriched fusion proteins were further purified by protein electroelution from SDS-PAGE gels. In brief, following separation by SDS-PAGE, the protein bands were visualized by briefly staining the gel in 0.25 M-KC1 containing 0.001% (v/v) 2-mercaptoethanol. The fusion protein was excised from the gel, and the protein recovered by elution using an electroeluter according to the manufacturer's (Bio-Rad) instructions. Electroeluted fusion protein was dialysed against 2 litres of PBS with the same osmolality of mouse serum (MOBS, pH 7-2) overnight at 4 °C.
Production o fan tisera against gel-purified fusion pro teins and MCM V.
To raise antisera to gB, 50 gg of fusion protein, purified by electroelution, was dissolved in MOBS and then emulsified with 1 mg of aluminium hydroxide. The emulsified protein was injected into 8-week-old female, BALB/c mice by the intraperitoneal (i.p.) route. All mice were specific-pathogen-free and were purchased from the Animal Resources Centre, Murdoch, Western Australia. The mice were boosted twice at 3 week intervals with 20 gg of the fusion protein emulsified in aluminium hydroxide and bled 1 week after the final injection. To raise hyperimmune sera to MCMV, 8-week-old female BALB/c mice were inoculated by the i.p. route with 104 p.f.u, of MCMV and boosted by injection with 103 p.f.u. 4 weeks later. Mice were bled 14 days after the final inoculation and hyperimmune sera were pooled.
Western blotting. Proteins separated by SDS PAGE were electroblotted to nitrocellulose as previously described (Towbin et al., 1979) . Blots were incubated for 1 h with either anti-MCMV hyperimmune serum from BALB/c mice or with the anti-gB antiserum, both diluted to 1/50 in MOBS containing 2% skim milk powder. Following three washes with TBS containing 2% skim milk powder, the blots were incubated with an alkaline phosphatase, goat F(ab')~ anti-mouse IgG + IgM conjugate (Tago). Following three washes with TBS the reactivity of the hyperimmune serum or anti-gB antiserum with the bound proteins was detected by the addition of 5-bromo-4-chloro-3-indolyl phosphate (final concentration 330 ~tg/ml) and nitro-blue tetrazolium (final concentration 165 gg/ml) (BCIP/NBT) (Sigma) in alkaline phosphatase buffer (100 mM-NaC1, 5 mM-MgC12 and 100 mMTri~HC1, pH 9"5).
Neutralization assay. A neutralization assay based on plaque reduction was performed as described by Farrell & Shellam (1990) . In brief, serum samples were heated at 56 °C for 30 rain to inactivate serum complement. Serial dilutions of antisera were diluted in MEM in the presence or absence of 5 % rabbit serum as a source of complement, and incubated with K181 MCMV for 90 rain at 37 °C in 5% CO 2. Following incubation the virus-antibody mixture was added to washed MEF monolayers in the wells of 24-well tissue culture trays and incubated for a further 60 rain at 37 °C in 5 % CO 2. After incubation the virubantibody mixture was removed and replaced with MEM containing 1-75 % methyl cellulose (Fisher Scientific) and 2 % fetal calf serum. The MEF monolayers were stained with methylene blue after 4 days at 37 °C in 5 % CO 2 and the plaques counted. Neutralization titres were recorded as the dilution of antiserum which gave a 50 % reduction in plaque numbers relative to controls incubated in the absence of antisermn. Four replicates were performed for each dilution of the serum samples.
In vivo protection studies. Fifty gg of gel-purified gB fusion proteins BS, BE2 or SS, or of GST alone were dissolved in MOBS and then emulsified with 1 mg of aluminium hydroxide. The emulsified proteins were then injected into groups of five 8-week-old female BALB/c mice by the subcutaneous route. The mice were boosted twice at 3 week intervals with 20 gg of the gB fusion proteins or GST alone emulsified in aluminium hydroxide. One week after the final boost, all mice were challenged i.p. with 2 x 104 p.f.u, of salivary gland-propagated MCMV. Spleens from individual mice were excised 4 days later and virus titres in spleen homogenates were determined by plaque assay as described previously (Farrell & Shellam, 1991) . Mice in the positive control group were injected with 104 p.f.u, of MCMV by the i.p. route 5 weeks prior to MCMV challenge.
DNA sequencing. Following PCR amplification of gB DNA from MCMV field isolates, the amplified PCR products were purified by isopropanol precipitation and used as templates for DNA sequencing. Primers 1 and 2 were identical to the amplification primers and were used to sequence the N-terminal and C-terminal regions of gB, respectively. Primer 3 (5' CGGTGATATCTCGACGAC 3'), which spans nucleotides 1165-1148 of the complementary strand of the published gB coding sequence (Rapp et al., 1992) , was used to sequence an internal region of gB. Primer 4 (5' TGGCAGGGATTGAA-AGCGAAATCAC 3'), which spans nucleotides 1351-1375, was used to sequence the cleavage region ofgB. For certain MCMV field isolates the full-length gB gene could not be amplified using the primers flanking the coding region. Strains W3, W8, G6, K29 and W8211 were amplified using primers 4 and 2, and the shorter amplification product was used for sequencing. DNA sequencing was performed using a dsDNA cycle sequencing kit according to the manufacturer's (GIBCO BRL) instructions.
Results

Identification of four antibody-binding regions in MCMV gB expressed in E. coli
To localize antibody-binding sites, MCMV gB of the K181 strain was expressed in E. coli using the pGEX vector system as described previously (Smith & Johnson, 1988) . A set of 11 overlapping subfragments was generated by digesting plasmid pBR322-gB, or the amplified gB PCR product, with appropriate restriction enzymes (Fig. 1 b) . To ensure that the cloned fragments were in the correct reading frame, fragments BS (residues 1-79), BA (residues 1-17), AS1 (residues 17-79) and SS (residues 809-926) were inserted into pGEX-1. Fragments BE1 (residues 1-278), EE (residues 290-508), EB (residues 290-389), PA (residues 626 676) and AS2 (residues 676-809) were inserted into pGEX-2T. Fragments BE2 (residues 155-278) and BB (residues 347-648) were inserted into pGEX-3X. For ease of plasmid construction, fragments BE1, BS and BA also contain 29 bp of non-coding sequence up-stream from the start codon of the gB open reading frame (ORF) (Fig. 1 c) .
Following induction of E. coli XL-1 blue cultures transformed with each construct, whole cell lysates were analysed on Coomassie-stained SDS-PAGE gels (Fig.  2a) . All fusion proteins, except the fragment BB were stably expressed to a high level. Fragment BB did not give rise to a protein of the predicted size of 59 kDa. Instead, a major polypeptide with molecular mass of 43 kDa was detected. This may indicate that BB was cleaved or degraded. Attempts to purify the gB fusion proteins using conventional affinity chromatography on immobilized glutathione were unsuccessful due to their insolubility. However, large quantities of all fusion proteins were readily enriched and partially purified by repeatedly washing the inclusion bodies and solubilizing with urea.
To map antigenic regions of MCMV gB, the fusion proteins were tested for reactivity with hyperimmune serum from BALB/c mice infected with the K181 strain of MCMV. GST alone and the fusion proteins BA, EB, PA and AS2 did not react with hyperimmune serum, whereas the fusion proteins BE1, BS, AS1, BE2 and SS showed strong reactivity on Western blots, and EE and BB showed weak reactivity (Fig. 2b) . The results obtained indicate that antibodies to MCMV gB are present in sera from MCMV-infected mice and that antibody-binding sites can be localized to three major regions, corresponding to amino acid residues 17-79, 155-278 and 809-926. In addition, a minor antibodybinding site can be localized to a region spanning residues 347-508. 
Assessment of neutralizing antibody-binding regions of M C M V gB and their ability to elicit protection in vivo
To determine if any of the identified antigenic domains induce antibodies that can neutralize virus infection, antisera were raised in mice to the GST-gB (BS, BE2 and SS) fusion proteins and tested for neutralizing activity in a plaque reduction assay. The anti-gB (BE2) antiserum showed moderate neutralizing activity which was dependent on the presence of complement (Table 1) . The antisera raised to the BS and SS fusion proteins had no significant neutralizing activity. Hyperimmune serum to MCMV was also included for comparison in the neutralization assay. The results obtained here show that amino acid residues 155-278 contain an antibodybinding region which elicits complement-dependent neutralizing antibodies. To test whether the antigenic region BE2, which elicits in vitro complement-dependent, neutralizing antibodies, is capable of restricting virus replication in vivo, the effect of an antibody response to the BE2 fusion protein on MCMV replication in the spleen was studied. Four groups of five BALB/c mice were immunized three times with fusion proteins BS, BE2 or SS, or GST alone as described in Methods. At 7 days after the final immunization mice were challenged with 2 x 104 p.f.u, of MCMV. Four days post-infection spleens were removed from all groups of mice, and virus titres in the spleens of Fig. 3 . Virus titres in the spleens of mice immunized with the recombinant gB fusion proteins and challenged with MCMV. Groups of five mice were immunized as described in Methods prior to challenge with 2 x 104 p.f.u, of MCMV. Virus titres in the spleens of mice at 4 days after infection were determined by plaque assay and are expressed as the mean p.f.u./g spleen _+ SEM. P values relative to the GST alone control group are also shown.
individual mice determined. In addition, a group of mice was immunized i.p. with 104 p.f.u, of MCMV 5 weeks prior to the MCMV challenge. No significant protective effect of prior vaccination with fusion proteins BS and SS was evident (Fig. 3) . In contrast, prior immunization with the fusion protein BE2 resulted in a moderate but significant reduction in MCMV replication in the spleen, and immunization with infectious MCMV provided complete protection against subsequent viral challenge. This result indicates that active immunization of mice with the fusion protein BE2 reduced the level of MCMV replication in the spleen.
Characterization of the glycoprotein molecules encoded by M C M V gB
To characterize the glycoprotein species derived from the gB ORF, the polyclonal antibodies raised against the truncated gB fusion proteins were used in Western blotting. The anti-gB (BE2 and BS) antisera reacted with a 105 kDa protein in purified virions, whereas the antigB (SS) antiserum was reactive with a 52 kDa protein in purified virions (data not shown). An analysis of the reactivity of the anti-gB (SS) antiserum with purified virions of MCMV isolates showed that it reacted with a 52 kDa protein present in all isolates (Fig. 4) . The strains tested include K4, K6, K7, K17E, N1, GIA, G2, G3A, W2, W5, W6 and W8, all of which are genetically distinct and differ biologically in their growth properties in vivo (Booth et al., 1993) . These results suggest that the cleavage of the precursor protein gp 150 (Loh et al., 1988; Loh, 1991) has occurred in all MCMV isolates tested. 
MCMV strain-common and MCMV strain-specific antibody-binding regions of gp52 and gpl05
To analyse whether the identified antibody-binding regions were conserved or variable, a panel of MCMV isolates (Booth et al., 1993) was tested for reactivity with the polyclonal anti-gB antisera by Western blot analysis. Hyperimmune serum to the K181 strain of MCMV showed a similar level of reactivity with all the infected MEF lysates (data not shown). The anti-gB (SS, BE2 and BS) antisera all predominantly reacted with a 130 kDa polypeptide in the MEF lysates, presumably representing the gp128 molecule ofgB reported previously (Loh et al., 1988; Rapp et al., 1992) . The anti-gB (SS) and anti-gB (BE2) antisera were reactive with a 130 kDa polypeptide in infected MEF lysates for each of the MCMV isolates tested (data not shown). These were: G1A, G2, G3A, G3B, G3E, G4, G5, W2, W3, W4, W5, W7, WE6, W8211, W9077, K4, K6, K7, K10, K17A, K29 and N1. In contrast, the anti-gB (BS) antiserum showed reactivity only with G1A, G3B, W2, W3, W4, W5, W8211, W9077, K4, K7, K10, K17A and K29, but not with the remaining isolates. These results indicate that the antibody-binding regions spanning residues 809-926 and 155-278 are conserved among the MCMV isolates tested, whereas the antibody-binding region corresponding to residues 17-79 is strain-specific.
Comparative sequence analysis of the antibody-binding regions of gB of MCMV isolates
To define at the sequence level the basis of variation in antibody-binding, the DNA sequences that encode the identified antibody-binding regions and also from around the proposed cleavage region of the gB molecule were determined. Glycoprotein B encoded sequences were obtained from the MCMV K181 laboratory strain and MCMV field isolates following PCR amplification from viral DNA. Deduced amino acid sequences derived from the regions corresponding to BS, SS (partial) and BE2 (partial) are presented in Fig. 5 (a, b, c, respectively) . Not all the isolates could be amplified by PCR. This was probably due to variation in the primer binding sequences of some of the isolates. The data presented here represent those isolates that could be amplified. Amino acid sequence variation in the BS region (residues 1-80) was found in isolates G3E, G4, G5, K17B, K6 and N1 (Fig. 5a ). The level of amino acid identity in the BS region among MCMV field isolates ranged from 88.8-100 %. Interestingly, two common variant residues were found in isolates G3E, G4, G5, K6 and N1. These were a glutamic acid instead of a glycine at residue 71 and a glycine instead of a glutamic acid at residue 60. These data were consistent with the observation that these strains did not react with the anti-gB (BS) antiserum raised against the BS region and may imply that the major antigenic epitope of this region contains one or other of these two residues. In contrast to the BS region, the SS and BE2 regions appeared to be relatively highly conserved at the amino acid level (Fig. 5 b, c) . For the SS region, most strains showed a single amino acid variation at position 890, but this change did not appear to affect the antibody binding. Some virus strains showed significant variation at the nucleotide level in the BE2 region but, with the exception of an isoleucine to valine change at residue 188, this was a result of third-base substitutions leading to silent mutations. The DNA sequence of the region flanking the proposed proteolytic cleavage site (Rapp et al., 1992) was also determined for K181 and 13 MCMV field isolates, and the comparison of the deduced amino acid sequences with those of the Smith strain is shown in Fig. 5(d) .
Comparison of the gB sequence of the Smith strain with those of the MCMV field isolates revealed that amino acid identity ranged from 83 100 %. Sequence variation was not distributed randomly and the greatest variability in amino acid sequence was found flanking the proposed cleavage site at residues 494-500. It is of interest to note that a number of the isolates had insertions and/or deletions in certain amino acid residues in the region immediately upstream of the proposed cleavage site. The proposed cleavage site motif RRKR/SFD~o 0 itself is relatively conserved. Two amino acid substitutions were found within the cleavage site motif in isolates G3E, G6, K29 and K17E. These were a leucine instead of a phenylalanine at residue 499, and an asparagine instead of an aspartate at residue 500. One amino acid substitution was found in isolate W8, which has a leucine instead of a phenylalanine at residue 499. Silent mutations also occurred at codons 494, 495 and 500 in these isolates. These substitutions in the proposed cleavage site motif did not appear to affect cleavage, as gp52, the C-terminal portion of gB, was detected in purified virions of the W8 and K17E MCMV isolates which contain these variant sequences (Fig. 4) .
Taking all the sequence data together for the BS, BE2, SS and cleavage regions, the MCMV isolates tested can be grouped broadly into three subgroups. Group 1 includes K181, K17A and K4, whose gB sequences are mostly identical to the Smith strain in the regions investigated. Group 2 includes N1, K6, G5, G4, W3 and W8211, which show medium levels of sequence variation compared with the Smith strain. Group 3 includes W8, G3E, G6, K17B, K17E and K29, which have the greatest sequence variation. This grouping bears no relationship to the location in which the isolates were obtained (Booth et al., 1993) . The K17A, K17B and K17E MCMV isolates, which were derived from the same wild mouse, all exhibited sequence heterogeneity within gB. KITE   G3E   1  i0  20  30  40  50  60  70  80   I  I  I  I  I  I  I  I  I   MS RRNERGCRS  S SWYAMSTALAVT  IWCLLACT  SEVIAAASTPGTTPKAKTD  TS S Fig. 5 . Comparison of the deduced amino acid sequences of the laboratory strain K181 and MCMV field isolates. All strains are compared to the published Smith strain sequence (Rapp et al., 1992) shown to the top of each figure 
Discussion
In this study, we have identified three major and one minor antibody-binding regions of the gB molecule of MCMV based on the reactivity of anti-MCMV antiserum with GST-gB fusion proteins expressed in E. coli. The major antibody-binding regions were mapped to amino acid residues 17-79, 155-278 and 809-926 using a series of truncated gB constructs, and the minor region was mapped to amino acid residues 347-508. Analysis of the translated gB sequence indicates that regions which encompass the identified antibody-binding sites have multiple areas with high levels of hydrophilicity (Fig.  1 a) , high antigenic indices and surface probability (data not shown). However, because the truncated gB fragments were expressed in a prokaryotic host, these antibody-binding regions, which probably represent linear or conformation-independent epitopes, may not fully reflect the complete antigenic properties of gB, and the presence of additional conformation-dependent epitopes on the native molecule cannot be excluded. Indeed, a number of conformation-dependent epitopes have been identified for HCMV around the cleavage region of HCMV gB (Utz et al., 1989; Qadri et al., 1992) . The weak reactivity of hyperimmune serum with the fusion proteins BB and EE, which map to the vicinity of the cleavage region of MCMV gB, may indicate that antibodies which recognize conformation-dependent epitopes do not fully bind to the E. col#expressed fusion proteins. The location of antibody-binding regions of MCMV gB spanning residues 17 79 and 809-926 is consistent with findings in HCMV gB (Meyer et al., 1990; Basgoz et al., 1992; Kniess et al., 1991) . The antibody-binding region corresponding to residues 155-278 of MCMV gpl05 has not been reported previously at the comparable region of HCMV gB. Antibodies to the BE2 region of the 105 kDa protein of MCMV gB exhibited moderate neutralizing activity with a titre of 1/640 in the presence of complement. Interestingly, all of the neutralizing antibodies to MCMV gB reported thus far have been found to be complementdependent (Rapp et al., 1992; Loh et al., 1988) . Immunization of mice with the fusion protein BE2 led to a moderate but significant reduction in the level of viral replication in the spleen following MCMV challenge. Similar levels of protection have been observed following immunization of mice with a nonapeptide representing the immunodominant cytotoxic T cell epitope present in the pp89 molecule of MCMV (Scalzo et al., 1995a) . The results obtained here indicate that the BE2 region encompasses a protective, complement-dependent neutralizing domain. Loh et al. (1988) have described a neutralizing monoclonal antibody which reacted with gp 105, but the relevant antigenic region was not mapped.
A number of neutralizing epitopes have been reported on HCMV gB (reviewed by Rasmussen, 1993) . However, to date there have been no neutralizing epitopes reported to exist on HCMV gB at a site corresponding to the BE2 region (residues 155~78) of MCMV gpl05. The antibodies raised against the C-terminal region of MCMV gp52 were not neutralizing. It is likely that this part of gp52 is localized on the inside of the virion or the cytoplasmic surface of the infected cell membrane and is probably not involved in neutralization, as has also been shown to be the case for gp58 of HCMV (Basgoz et al., 1992; Kniess et aL, 1991) .
Any exploitation of a particular viral protein for inclusion as a component of a subunit vaccine will also depend on how well the neutralizing epitope is conserved among different virus isolates. To this end, the antibodybinding regions were evaluated to determine whether they are conserved or strain-specific among the MCMV isolates. The antibody-binding region at the N-terminal region of MCMV gB defined by the anti-gB (BS) antiserum appears to be strain-specific in reactivity. Similarly, the antibody-binding region spanning residues 28-67 of the HCMV gB is also strain-specific (Basgoz et al., 1992; Meyer et al., 1992; Lehner et al., 1991) . In contrast to the BS region, the antibody-binding regions spanning residues 155-278 and 809-926 are straincommon. The conserved, neutralizing antigenic region defined by BE2 indicates that this region could be an important candidate for inclusion as a component of a multimeric subunit vaccine if similar properties are demonstrated for HCMV gB.
To further examine the relationship of antibodybinding reactivity to the nucleotide sequence variation of antibody-binding regions of gB, several regions of gB from a number of MCMV isolates were sequenced. Consistent with the antibody recognition data, the amino acid sequences of the SS and BE2 regions were relatively highly conserved. While nucleotide sequence variation in this portion of the BE2 region was almost 10%, the nucleotide changes observed were principally in the third base of each codon, and hence resulted in silent mutations. In contrast, the BS region was quite variable at the amino acid level, with two variant residues at positions 60 and 71 commonly present in the MCMV strains which showed no recognition by the anti-BS antibody in Western blot analysis. It is possible that substitutions at these residues may lead to the lack of antibody recognition observed.
The region surrounding the proposed cleavage motif of MCMV gB had the greatest variability in amino acid sequence. This is consistent with findings for the level of sequence heterogeneity around the HCMV gB cleavage region (Chou & Dennison, 1991) . A high degree of variation around the cleavage region might suggest that this area of CMV gB represents a target for immunological pressure. The consensus cleavage sequence (K/R)T(K/R)R/ST appears to be conserved in all strains of HCMV gB (Chou & Dennison 1991 ; Spaete et al., 1990) . The proposed cleavage motif of MCMV gB (RRKR/SFDs00; Rapp et al., 1992) showed two substitutions at positions 499 and 500. Despite this, MCMV strains possessing this variant sequence still underwent proteolytic cleavage as demonstrated by the presence of gp52 in purified virions of the isolates W8 and K17E, which demonstrate amino acid variation in this motif (Fig. 4) . This suggests these substitutions do not affect recognition by the enzyme mediating proteolytic cleavage.
The observation in this study of a high degree of conservation of amino acid sequence in the BE2 region, despite the presence of a neutralizing, antibody-binding region, is somewhat paradoxical. This finding may imply that this region is functionally important and that genetic variation leading to changes in amino acids cannot be tolerated, or that this region is not a major determinant of gB-mediated neutralization in vivo in antisera induced following natural infection. The precise consequences of the sequence variation on immunological recognition and the effect on the biological function of MCMV gB remain to be determined.
